CVS Caremark (CVS) Tops Q2 EPS by 3c; Boosts FY14 EPS Midpoint Guidance
Get Alerts CVS Hot Sheet
Revenue Growth %: +4.8%
Financial Fact:
Operating profit: 2.82B
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
(Updated - August 5, 2014 7:10 AM EDT)
CVS Caremark (NYSE: CVS) reported Q2 EPS of $1.13, $0.03 better than the analyst estimate of $1.10. Revenue for the quarter came in at $34.6 billion versus the consensus estimate of $33.47 billion.
Same store sales increased 3.3% versus the second quarter of last year, with pharmacy same store sales up 5.0% and front store same store sales down 0.4%. Pharmacy same store prescription volumes rose 3.9% on a 30-day equivalent basis.
The Company raised and narrowed its earnings guidance range for the full year 2014. The Company now expects to deliver Adjusted EPS of $4.43 to $4.51, up from $4.36 to $4.50. Consensus expectations are at FY14 EPS of $4.46.
The Company expects to deliver Adjusted EPS of $1.11 to $1.14 and GAAP diluted EPS from continuing operations of $1.04 to $1.07 in the third quarter of 2014. The Street sees Q3 EPS of $1.13.
For earnings history and earnings-related data on CVS Caremark (CVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Walgreens Boots Alliance (WBA) Tops Q2 EPS by 38c, Offers Guidance
- Pulse Biosciences, Inc. (PLSE) Tops Q4 EPS by 2c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot Guidance, Retail SalesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!